Top Peptides for Body Recomposition: Fat Loss + Muscle Gain

AOD-9604 — The Fat-Specific GH Fragment

AOD-9604 (Advanced Obesity Drug) is a modified fragment of human growth hormone — specifically amino acids 177-191 of the GH molecule, with an added tyrosine residue. The critical insight behind AOD-9604 is that the lipolytic (fat-burning) effects of growth hormone are mediated by a different region of the molecule than the growth-promoting effects. By isolating this fragment, researchers aimed to capture GH’s fat-burning properties without the diabetogenic and proliferative side effects of full-length GH.

The Evidence

The foundational research comes from Ng and Borstein at Monash University. Their work demonstrated that AOD-9604 stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat synthesis) in both animal models and human adipose tissue explants. In obese Zucker rats, AOD-9604 reduced body fat by 50% over 19 days without affecting IGF-1 levels or glucose tolerance — a crucial distinction from full-length GH, which worsens insulin sensitivity.

A Phase 2 clinical trial (Stier et al., 2013) in 300 obese adults showed modest weight loss (2.6 kg over 12 weeks with the oral formulation), though the results were not considered clinically significant enough to pursue FDA approval for obesity. However, the trial confirmed the compound’s safety profile and its lack of effect on IGF-1, glucose, or insulin levels.

Recomp Relevance

AOD-9604’s value for recomposition is its specificity: it mobilizes fat stores without the muscle-building or glucose-disrupting effects of GH. When combined with a GH secretagogue stack (like Ipamorelin + CJC-1295) that handles the anabolic side, you get a two-pronged approach — one arm building lean mass, the other stripping fat.

• Typical protocol: 300-600 mcg/day subcutaneously, ideally fasted (morning or pre-exercise)
• Cycle length: 8-12 weeks
• Often stacked with: Ipamorelin, CJC-1295, or Tesamorelin

Tesamorelin — Visceral Fat Destroyer

Tesamorelin deserves a dedicated section in any recomp discussion because it’s the only FDA-approved GHRH analog with trial data specifically demonstrating visceral fat reduction. The Phase 3 LIPO trials showed a 15-18% reduction in visceral adipose tissue at 26 weeks — this is the deep abdominal fat that wraps around organs and drives metabolic dysfunction.

Simultaneously, tesamorelin elevated IGF-1 levels by 80-100% from baseline, creating an anabolic hormonal environment that supports lean mass preservation. While the trials weren’t designed to measure muscle hypertrophy per se, the combination of reduced VAT + elevated IGF-1 is the textbook hormonal profile for recomposition.

Why Visceral Fat Matters

Visceral adipose tissue isn’t just cosmetically undesirable — it’s metabolically active tissue that secretes inflammatory cytokines (IL-6, TNF-alpha), disrupts insulin signaling, and contributes to systemic inflammation. Reducing VAT improves insulin sensitivity, lowers inflammation, and creates a metabolic environment that’s more conducive to partitioning nutrients toward muscle rather than fat storage. Tesamorelin addresses the root cause, not just the symptom.

• Protocol: 2 mg subcutaneously once daily (FDA-approved dose)
• Cycle length: 12-26 weeks based on clinical trial durations
• Note: Effects reverse upon discontinuation — VAT begins to re-accumulate within 12 weeks of stopping

MOTS-c — The Mitochondrial Exercise Mimetic

MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is one of the most scientifically fascinating peptides on this list. It’s a mitochondrial-derived peptide — one of the very few signaling molecules encoded by mitochondrial DNA rather than nuclear DNA. Its primary mechanism involves activation of the AMPK pathway, the same master metabolic switch activated by exercise and caloric restriction.

The Evidence

The landmark study by Lee et al. (2015, Cell Metabolism) demonstrated that MOTS-c treatment in mice prevented age-dependent and high-fat diet-induced insulin resistance, increased fatty acid oxidation, and improved overall metabolic function. Mice treated with MOTS-c showed significantly less fat accumulation when fed a high-fat diet compared to controls — without changes in food intake.

A follow-up study (Lee et al., 2019) showed that MOTS-c levels increase in skeletal muscle during exercise and that exogenous MOTS-c administration improved physical performance in aged mice — running time increased by 80% compared to untreated aged controls. The mechanism involves enhanced skeletal muscle glucose uptake via GLUT4 translocation and improved mitochondrial function.

Recomp Relevance

MOTS-c hits both sides of the recomp equation: it enhances fat oxidation (energy substrate utilization) while improving skeletal muscle metabolic function and glucose uptake. It essentially makes muscle tissue more metabolically efficient — better at using fuel, more responsive to insulin, and more resilient to metabolic stress.

• Typical protocol: 5-10 mg subcutaneously, 2-3x per week
• Cycle length: 8-12 weeks
• Best paired with: Regular exercise (MOTS-c amplifies exercise adaptations rather than replacing them)

5-Amino-1MQ — NAD+ Booster and Fat Oxidizer

5-Amino-1-methylquinolinium (5-Amino-1MQ) is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that plays a role in energy metabolism and adipogenesis. NNMT consumes methyl donors and degrades nicotinamide (a precursor to NAD+). By inhibiting NNMT, 5-Amino-1MQ increases intracellular NAD+ levels and S-adenosylmethionine (SAM) availability — both of which are critical for cellular energy metabolism.

The Evidence

Neelakantan et al. (2018, Biochemical Pharmacology) demonstrated that NNMT inhibition in mice fed a high-fat diet resulted in significant reductions in body weight and adipose tissue mass, along with reduced adipocyte size. Crucially, the treated mice showed no decrease in food intake — the weight loss was driven by increased energy expenditure, not caloric restriction.

The NAD+ connection is particularly relevant for recomposition: NAD+ is essential for mitochondrial function, and declining NAD+ levels are associated with age-related metabolic dysfunction, reduced fat oxidation capacity, and impaired muscle recovery. By restoring NAD+ levels, 5-Amino-1MQ may support both enhanced fat metabolism and improved muscle recovery.

• Typical protocol: 50-150 mg orally, 1-3x daily (one of the few in this list with oral bioavailability)
• Cycle length: 8-12 weeks
• Note: Relatively new compound in research — long-term human data is limited

Ipamorelin + CJC-1295 — The Anabolic Foundation

This combination appears in our muscle growth article as well, and for good reason — it’s the backbone of most peptide recomposition protocols. The GH elevation from this stack addresses both sides of the equation: growth hormone is simultaneously lipolytic (it mobilizes fatty acids from adipose tissue for oxidation) and anabolic (it stimulates IGF-1 production, which drives protein synthesis and satellite cell activation in muscle tissue).

For recomposition specifically, the timing of Ipamorelin administration matters. Dosing pre-sleep amplifies the natural nocturnal GH pulse, which is the body’s primary window for fat oxidation and tissue repair. Fasted morning dosing capitalizes on the already-low insulin environment to maximize lipolytic effects.

• Typical protocol: Ipamorelin 200-300 mcg + CJC-1295 (no DAC) 100 mcg, 2-3x daily (morning fasted + pre-bed at minimum)
• Cycle length: 12-16 weeks for meaningful recomp effects
• Synergistic stacking: Combines well with AOD-9604 (amplified fat loss) or MOTS-c (metabolic efficiency)

SLU-PP-332 — The Exercise Mimetic ERR Agonist

SLU-PP-332 is an ERR-alpha/gamma (estrogen-related receptor) agonist that emerged from research at Washington University in St. Louis. ERR receptors regulate genes involved in mitochondrial biogenesis, fatty acid oxidation, and oxidative muscle fiber development. In essence, activating these receptors mimics some of the molecular adaptations that occur with endurance exercise — increased mitochondrial density, enhanced fat-burning capacity, and a shift toward oxidative muscle fiber types.

The Evidence

Kim et al. (2023, preclinical data presented at the American Chemical Society Spring Meeting) showed that mice treated with SLU-PP-332 developed 10x more fatigue-resistant muscle fibers than untreated controls. The compound increased the proportion of type I (slow-twitch, oxidative) muscle fibers — the fiber type associated with endurance, leanness, and metabolic health.

Mice treated with the compound also gained 10% less weight than controls when both groups were fed a high-fat diet, despite similar food intake. The mechanism is increased baseline energy expenditure driven by the metabolic cost of maintaining more mitochondria-dense muscle tissue.

Practical Considerations

• Status: Preclinical — no human dosing data available as of 2026
• Administration: Oral (small molecule, not a peptide technically)
• Research interest: High — represents a novel approach to recomp by fundamentally altering muscle fiber composition and metabolic capacity
• Caveat: Very early-stage. Include this on your watch list, not your shopping list.

Building a Recomp Protocol: Practical Considerations

A few principles for researchers designing body recomposition protocols:

• Nutrition is still the foundation. Peptides modulate metabolism — they don’t override it. A slight caloric deficit (200-300 kcal/day) or maintenance calories with high protein (2.0+ g/kg/day) is still required to create the conditions for recomposition.
• Resistance training is non-negotiable. Without the mechanical stimulus for muscle growth, even the most potent anabolic peptide stack won’t produce meaningful hypertrophy. Train with progressive overload 3-5x per week.
• Stacking requires logic. Combine compounds that target different pathways — e.g., GH secretagogue (anabolic) + AOD-9604 (lipolytic) + BPC-157 (recovery). Don’t stack three compounds that all do the same thing.
• Monitor bloodwork. At minimum: fasting glucose, insulin, IGF-1, complete metabolic panel, lipid panel. Every 4-6 weeks during a protocol.
• Be patient. Recomposition is inherently slower than pure cutting or bulking. Expect visible changes at 8-12 weeks with consistent training, nutrition, and protocol adherence.

This article is for educational and research purposes only. These compounds are intended for use in controlled research settings. Always comply with local regulations and consult qualified professionals.